

VRL/SEC/EXCHANGE

08.12.2025

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai Script Code: 526953
--	---

Sub: Announcement: Venus Remedies Marks Completion of AMR Licensing Milestones with Final ₹11 Crore Payment

Dear Sir/Madam,

Kindly find enclosed herewith an announcement being made by Venus Remedies Limited on the captioned subject.

You are requested to take the above information on record.

Thanking you
Yours faithfully,
for VENUS REMEDIES LIMITED


Neha
(Company Secretary)
M. No. F8374

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com

www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany



Venus Remedies Marks Completion of AMR Licensing Milestones with Final ₹11 Crore Payment

India, December 08, 2025: Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) today announced the receipt of the final anticipated milestone payment of ₹11 crore from Cipla Ltd, marking the successful completion of all anticipated commercial milestones agreed under the 2019 arrangement for its novel AMR-focused anti-infective in the Indian territory.

The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019 for marketing and distribution in India. Cumulatively, the product has delivered therapeutic benefits to over one million patients throughout its lifecycle. No serious drug-related adverse events have been reported in post-marketing experience, reflecting a favourable safety profile in real-world use.


Designed to address treatment gaps where conventional antibiotics often fail, this AMR-targeted therapy has become an important option in hospital practice and stands as a significant example of indigenous innovation delivering sustained clinical impact in a high-burden setting like India.

Commenting on the milestone, **Mr. Saransh Chaudhary**, President, Global Critical Care, Venus Remedies Ltd, and CEO, VMRC, said:

“The receipt of this final anticipated milestone payment is more than a financial outcome; it is a strong validation of the long-term clinical and commercial relevance of our AMR-focused research. Seeing a home-grown anti-infective reach over a million patients while meeting all performance targets agreed with our partner is deeply encouraging for our teams.

For Venus Remedies and VMRC, this success reinforces our commitment to sustained innovation in AMR. Our pipeline includes differentiated antibacterial candidates such as VRP-034 and MET-X, both granted QIDP designation by the US FDA, alongside ongoing work in surveillance and stewardship through programmes like GASAR and international data-sharing collaborations. We remain focused on *developing scientifically robust, clinically meaningful solutions that help preserve the effectiveness of antibiotics and improve outcomes for patients facing serious infections.*”

The company will continue to prioritize AMR as a core strategic area, combining innovation, evidence generation and responsible use frameworks to address one of the most urgent healthcare challenges of this century.





About Venus Remedies Limited

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with 180+ product basket and 1050+ marketing authorizations, spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.

Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β -lactam/ β -lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.

